Close Menu
    What's Hot

    Editor’s Letter – Volume 2, Issue 8, August 2026

    August 12, 2026

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026
    X (Twitter) LinkedIn
    Longevity & Mortality Investor
    • Home
    • Coverage
      1. Life Insurance Capital Solutions
      2. Life Insurance
      3. Longevity and Mortality Risk Transfer
      4. Mortality
      5. Secondary Life Markets
      6. View All

      Lincoln Financial Reinsures Universal Life Block With Talcott

      August 3, 2026

      US Annuity Sales Set New Quarterly Record in Second Quarter

      August 3, 2026

      Big Year of Growth for Life/Annuity Sidecar-Like Activity in 2025

      July 2, 2026

      Sixth Street To Become Majority Shareholder of Monument Re

      June 30, 2026

      Shaping the Future of Health Insurance Through Innovation and Analytics

      June 10, 2026

      Q&A: Dr Christoph Schmitt, Director, Insurance, Fitch Ratings

      May 28, 2026

      Chronic Disease Onset and Cumulative Exposure: Clinical, Prognostic and Underwriting Implications

      May 13, 2026

      US Annuity Sales Notch Tenth Consecutive $100bn+ Quarter

      May 11, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026

      Elementis Group Pension Scheme Completes Bulk Purchase Annuity Buy-In With Aviva

      August 5, 2026

      Hickson UK Group Pension Scheme Completes Bulk Purchase Annuity Transaction With Royal London

      August 3, 2026

      UK Insurance Company Pension Scheme Completes Bulk Purchase Annuity Transaction With M&G

      August 3, 2026

      Record Low Mortality Rates So Far in England and Wales in 2026

      July 9, 2026

      Organ Transplant Improvements Test Life Expectancy Assessment Models

      July 8, 2026

      The Pursuit of Everlasting Life Unlikely to Shift Actuarial Models

      June 10, 2026

      Pricing in the Unknown: Why Mortality Models Aren’t Ready for MCED Tests Just Yet

      April 9, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      Corry Capital Advisors Adds John Daniel as Senior Director of Analytics and AI Strategy

      August 6, 2026
      European Life Settlement Association

      ELSA Publishes Latest Life Settlement Licence Matrix 2026 Fact Sheet

      August 6, 2026

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

      August 12, 2026

      The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

      August 12, 2026

      US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

      August 12, 2026
    • Events
    • Latest Issues

      Editor’s Letter – Volume 2, Issue 8, August 2026

      August 12, 2026

      Editor’s Letter – Volume 2, Issue 7, July 2026

      July 8, 2026

      Editor’s Letter – Volume 2, Issue 6, June 2026

      June 10, 2026

      Editor’s Letter – Volume 2, Issue 5, May 2026

      May 13, 2026

      Editor’s Letter – Volume 2, Issue 4, April 2026

      April 9, 2026
    • Contact Us
    Newsletter
    Longevity & Mortality Investor

    Despite Bumpy Couple of Years, Lessons Learned Stand Life ILS Market in Good Stead

    Life Insurance Capital Solutions February 14, 2024By Greg Winterton
    Share
    Twitter LinkedIn Email

    The alternative credit industry experienced something of an up-and-down year in 2023. On one hand, fundraising pulled back as investors rotated into more liquid, higher yielding credit investments, and on the other, existing funds, particularly in the private debt space, with floating rate loans enjoyed higher returns. 

    The impact of higher interest rates was certainly felt keenly in the life ILS corner of the alternative credit space last year, in both capital raising and deal activity. In the former, the reasons were consistent with the alternative credit market at large.  

    But in deal flow, certain trades experienced a retraction in activity. One example is value in force (VIF) deals, a transaction where asset managers pay a discounted upfront cash sum to an insurer in return for the payment stream of a block of insurance policies. 

    “The rise in interest rates in conjunction with a widening of risk spreads has led to higher absolute costs of financing which has presented challenges to investment counterparties. That higher cost of financing has an impact on the appetite for certain VIF structures because sellers and suppliers of risk are having to pay more than in the past. Some counterparties are questioning whether or not they’re comfortable printing at the top of the cycle,” says Craig Gillespie, Head of Life and Alternative Credit at investment manager, Leadenhall Capital Partners. 

    But whilst there may be a contraction in the supply of VIF transactions, higher rates are providing an opportunity for managers in the space to be more selective with regards to the deals that they do underwrite. 

    “Insurance businesses that still have a need for capital or liquidity have had to pay up the increased all in rates of financing. There’s been something of a flight to quality, where we’ve focused on working selectively with the best counterparties and pipeline opportunities in the market – there’s the opportunity to earn an increased spread whilst taking less risk than in recent periods. We’re being more prescriptive in terms of where we allocate capital,” added Gillespie. 

    In January, the US Federal Reserve kept its Federal Funds Rate flat for the fourth consecutive time, and the European Central Bank’s three main interest rates also remained constant. The UK’s Bank of England hasn’t increased its Base Rate since last August. Couple this with falling inflation adds up to encouragement in consumer and political circles that the recent rising interest rate regime has plateaued. But, even if markets are now at the top of the interest rate cycle, and at some point this year, interest rates began to fall, the floodgates won’t necessarily re-open. 

    That’s because both the Covid-19 pandemic and the recent macroeconomic environment have had something of a longer-term impact on the life ILS market, conspiring together to force investors in the market to re-evaluate certain aspects of their deal origination function. 

    “Covid underlined the fact that, from an actuarial perspective, populations are not created equally. During the pandemic, certain socio-economic groups were impacted by excess mortality more than others. General population mortality-based investment structures haven’t fared very well in the past few years, which means that our underwriting efforts are being further refined according to the underlying population exposure,” says Gillespie. 

    Recent macroeconomic events and the stronger volatility and uncertainty have also had an impact on how insurance companies approach capital solutions. 

    “In general, we see a strong increase in derisking and capital management activity in the European life insurance landscape. The bulk of the risk goes to the reinsurance industry but clearly Life ILS can play an increasingly relevant role moving forward. Whereas in the past the role of Life ILS was predominantly on the financing front, the end investors often now require ILS managers to revert to more biometric risk-driven investments or, ‘back to basics’ as they like to say,” says Luca Tres, Head of Strategic Risk and Capital Life Solutions, EMEA at insurance consulting firm, Guy Carpenter. 

    However, there is still, and will always be, appetite for financing solutions from the life insurance segment. 

    “Sitting in-between capital markets and the life (re)insurance industry, the Life ILS market introduces a differentiated capacity in the financing space, specifically for opportunities with a strong biometrical or lapse component. Therefore, it is clear that Life ILS will continue to be a strategic partner for the life (re)insurance industry”, adds Tres.  

    There’s a saying in the family office space that when you’ve met one family office, you’ve met one family office. The same could be said for the life ILS industry; not all asset managers enter into the same types of transactions, leading to less homogeneity within the space when compared to, say, the non-life ILS catastrophe bond market. The complexity of insurance-linked transactions when compared to other alternative credit strategies means that investor education is ongoing, and macroeconomic cyclicality has impacted the space like it has many private markets strategies.  

    But for Gillespie, the lessons of the past few years will prove beneficial in the medium to longer term, and overall, the message to investors remains. 

    “The life ILS space has actually been around for many years, but for the first 10, it was a relatively benign market. We’ve had two major tests in the last five years that have put certain investment structures to the test. These tests have helped the life ILS market to understand where the true risk premiums should lie, and whether these are aligned to the actual losses that could materialise when an event happens,” he says. 

    “This development in itself hasn’t changed the investment case for life ILS. The demand from life insurers and other life-linked insurance businesses for financing solutions is there. The supply of capital is there because investors need and want medium to long-dated exposures that offer differentiated risk-return profiles to the main capital markets. If anything, the events of the past few years have served to strengthen the offering by making the investment processes that underpin it more robust.” 

    2024 - February Life ILS Volume 3 Issue 2 - February 2024
    Share. Twitter LinkedIn Email

    Related Posts

    Capital Markets Investors Could Be About to Get a Slice of UK Life Insurance Risk

    November 26, 2025By Greg Winterton

    Is It Time to Rate Life ILS Structures?

    October 22, 2025By Greg Winterton

    Q&A: Chris Wells, Managing Editor, Longevity and Mortality Investor

    October 8, 2025By Greg Winterton

    HSCM Bermuda Closes Secondaries Fund to Acquire Life Insurance-Linked Securities Portfolio

    September 25, 2025By LMI Newsdesk
    Latest Issue

    New Life Settlement Provider Data Illustrates Continued Evolution of Secondary Life Settlement Market

    August 12, 2026

    The Crucial Role of Regular Medical Record Reviews in Life Settlement Investments

    August 12, 2026

    US Life Carriers Eyeing VM-22 for a Pension Risk Transfer Pricing Advantage in 2027

    August 12, 2026

    End-Game Clarity Shaping UK Pension Risk Transfer Market but Large Schemes Still on the Sidelines

    July 22, 2026
    Ad

    Where Longevity and Mortality Meet the Markets
    ISSN 2978-5219

    X (Twitter) LinkedIn
    Coverage
    • Life Insurance Capital Solutions
    • Life Insurance
    • Longevity and Mortality Risk Transfer
    • Mortality Risk
    • Secondary Life Markets
    More Info
    • Home
    • About Us
    • Contact Us
    • Guest Articles
    • Submit Story Idea
    Our Newsletter
    Get the latest industry news, commentary and events from the Longevity & Mortality Investor directly into your inbox. Why not sign up today?

    © 2026 Longevity & Mortality Investor. Website by Kavells.
    • Sitemap
    • Privacy Policy
    • Copyright Notice
    • Terms & Conditions

    Type above and press Enter to search. Press Esc to cancel.